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Abstract: A major rate-limiting step in nonviral gene delivery is the entry of nucleic acids 
across various membrane barriers and eventually into the nucleus where it must be transcribed. 
Cell-penetrating peptides and proteins are employed to generate formulations that overcome 
these challenges to facilitate DNA delivery into cells efficiently. However, these are limited by 
their inability to deliver nucleic acids selectively due to lack of specificity because they deliver to 
both cancer and normal cells. In this study, through modular design, we generated a recombinant 
fusion protein designated as Her-nuclear localization sequence (Her-NLS), where heregulin-α . 
(Her), a targeting moiety, was cloned in frame with cationic NLS peptide to obtain a cell-specific 
targeting biomolecule for nucleic acid delivery. The heregulin-α1 isoform   possesses the epider-
mal growth factor-like domain and binds to HER2/3 heterodimers which are   overexpressed in 
certain breast cancers. Purified recombinant Her-NLS fusion protein binds plasmid DNA and 
specifically transfects MDA-MB-453 cells overexpressing the epidermal growth factor receptors 
HER2/3 in vitro. The approach described would also permit replacement of heregulin ligand 
with other targeting moieties that would be suited to cell-specific nucleic acid delivery mediated 
via receptor-ligand interactions.
Keywords: cell targeting, nucleic acid delivery, nuclear localization sequences, heregulin, 
transfection, HER2 receptors
Introduction
The design of vehicles for safe and efficient delivery of nucleic acids into cells is 
critical to successful gene therapy protocols. However, the major obstacle is lack of 
efficient delivery methodologies. Peptide-based delivery systems permit   generation 
of diverse molecules that can potentially transfect and target cells with minimal toxic-
ity, and often efficiency is linked to design. Cell-penetrating peptides (CPPs) in gene 
delivery protocols, in the last decade, have gained attention due to their versatility,1–3 
because they are rich in basic residues, such as lysine and arginine. These peptides 
are able to condense DNA efficiently into small, compact nanoparticles through 
  electrostatic   interactions to generate multifunctional formulations of therapeutic 
value. The   advantages derived from short peptides in gene delivery protocols are due 
to their potential to overcome various barriers, including cell, endosomal, and nuclear 
membrane barriers. We recently characterized and explored the utility of several 
designed recombinant   peptides that are cationic in nature, nontoxic, and have novel 
transfection properties.4,5 These multidomain fusion peptides are primarily utilized in 
gene therapy protocols due to their increased efficiency that is comparable with that 
of existing commercial formulations.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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CPPs lack sequence similarity and specificity. However, 
due to their cationic nature, cell-  penetrating peptides have 
been used successfully to bind DNA and transfect cells. One 
of the early examples proposed for cell-specific DNA transfer 
is based on the chimeric multidomain fusion protein, where 
a single chain antibody domain that binds to the ErbB-2 
receptor was cloned with the exotoxin translocation domain 
of Pseudomonas and a DNA-binding domain.6 Complexes of 
plasmid DNA with the multidomain fusion protein were able 
to transfect ErbB-2-expressing tumor cells in vitro in a cell-
specific manner. ErbB-2, the human epidermal growth factor 
receptor, HER2/neu is a transmembrane protein that belongs 
to the epidermal growth factor receptor family. This gene is 
overexpressed in 15%–20% of breast cancers. Therapeutic 
agents against HER2/neu have been intensively sought over 
the last few years7,8 to treat a multitude of cancers. Recently, a 
study described the use of CPPs such as HIV-TAT conjugated 
to peptide mimetic carriers, to target ErbB2-overexpressing 
breast cancers specifically. Being a transducing moiety, TAT 
makes internalization highly   efficient while simultaneously 
delivering conjugated   molecules.9 Bidewell et al have investi-
gated the ability to target specific compartments10 with CPPs 
that are   beneficial in cancer therapy. In addition, the TAT 
epitope possesses an inherent nuclear localization signal that 
contributes to the enhanced transfection efficiencies observed 
by several laboratories. It is thus evident that the conjugation 
of peptide ligands to CPPs will permit targeting to receptors 
in a cell-specific manner and are therefore natural and safer 
alternatives to viral vectors.
Heregulin-α was originally purified from conditioned 
medium11 in a human breast cancer cell line, and identified 
to represent the natural ligand for HER2/ErbB2 with a single 
high affinity binding site. HER2/neu protein overexpression 
has been observed in non-small cell lung cancer, especially 
in lung adenocarcinoma.12 HER2 receptors are involved in 
the pathogenesis of various types of malignancies, including 
prostate, breast, ovarian, and lung cancer, and are therefore a 
good target for the specific introduction of nucleic acids into 
the cell. Through these studies, ErbB2 has been shown to be 
an ideal target for cancer therapies. Nearly a decade ago, a 
chimeric fusion of 10 lysine residues to the penton base of 
the adenoviral capsid protein was cloned in frame with the 
epidermal growth factor-like domain of the heregulin-α1 
isoform that targets breast cancer cells in a cell-specific 
manner.13 Such an approach may reduce the amount that is 
required for targeting with reduced toxicity. Although there 
have been considerable efforts worldwide to design efficient 
targeting vectors, the limitations of current DNA   transfection 
protocols have driven our attempt to identify and create 
  suitable transfection-efficient biomolecules for cell-specific 
targeting. Designer peptides with distinct DNA-binding 
epitopes or nuclear localization epitopes serve as nucleic acid 
binders, while the ligand that recognizes its   corresponding 
receptor will render cell specificity, thereby facilitating 
internalization of nucleic acids into cells.
Cell targeting has been demonstrated in yet another 
effort where a multidomain fusion protein was engineered 
to target cancer cells and also destabilize endosomal mem-
branes once internalized,14 thereby mediating efficient DNA 
  delivery. Strategies for delivering plasmids are also being 
used to deliver other therapeutic nucleic acids, such as short 
  interfering RNA (siRNA).7,15 Recombinant cationic fusion 
proteins can thus be harnessed to carry and deliver all types 
of nucleic acids in a cell-specific manner.
We recently demonstrated that fusion peptide TAT-
NLS-Mu (TNM), with three nuclear localization sequence 
(NLS) epitopes was more efficient than TAT-Mu4 which is 
devoid of these epitopes, suggesting a role of NLS in the 
engineered recombinant TNM peptide. In an elegant study, 
Subramanian et al conjugated the NLS motifs for DNA 
delivery by conjugating a nonclassical NLS M9 peptide16 
that resulted in increased reporter gene expression. Here, we 
report the generation of a heterologous His-tag fusion protein 
where a plasmid construct with three NLS moieties in tandem 
were cloned in frame with the heregulin-α   moiety, resulting 
in a chimera designated as Her-NLS, with the premise that 
the NLS epitope would facilitate the passage of DNA into 
the nucleus once delivered into the cytoplasm. The cloned 
heregulin-α moiety, with an epidermal growth factor-like 
domain would enable efficient targeting of DNA via specific 
receptors overexpressed in breast carcinoma cell lines. The 
ability to bind DNA, cell uptake, and the cell biologic   activity 
of purified recombinant protein that harbors the heregulin 
ligand fused in-frame with the NLS epitopes was investigated 
and demonstrated in this study.
Methods
Cells, plasmid constructs,  
and fusion peptides
Plasmids pHerPBK10, pRSET-Her, MDA-MB-231, and 
MDA-MB-453 human breast cancer cells was obtained 
from Medina-Lali Kauwe, University of Southern California 
Keck School of Medicine, Los Angeles, CA. Plasmids pEG-
FPN3 and pCMVβ-gal were from inhouse stocks. Plasmid 
  pEYFPNuc was obtained from David Dean’s laboratory, 
presently at the University of Rochester (Rochester, NY). International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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These cells were grown and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM)-F12, 10% fetal calf 
serum at 37°C, and 5% CO2. Oregon Green nucleic acid 
labeling kit was from Invitrogen (Eugene, OR). Protamine 
sulfate was from Sigma-Aldrich (St. Louis, MO). All other 
reagents were of the highest purity.
Construction and production  
of recombinant protein Her-NLS  
in Escherichia coli
Plasmid pTAT-NLS was generated by amplifying the NLS 
moiety from pEYFPNuc and cloning in frame with the TAT 
epitope of pTAT. For generating cell specificity and   cloning 
the cell-targeting ligand construct, the TAT moiety was deleted 
and the sites were used for inserting the polymerase chain 
reaction-amplified heregulin moiety. The gene for heregulin, 
the targeting ligand (0.6 kb), was amplified by   polymerase 
chain reaction (PCR) from the plasmid pHerPBK10, using 
  forward primer- 5′TCTGTACGACGATGACGATAAG-3′, 
and reverse primer-5′-GCATGGATCCACTTCCAC-3′ 
with BamHI sites incorporated for generating pHer-NLS. 
These plasmid constructs were verified by DNA sequenc-
ing to confirm the integrity of the cloned heregulin-α 
  targeting ligand and the DNA binding epitope. pHer-NLS 
was then transformed into Escherichia coli expression host 
BL21(DE3)pLysS and induced with isopropyl-beta-D-
  thiogalactopyranoside (IPTG). The histidine tag of the fusion 
protein   Her-NLS facilitates purification with cobalt affinity 
matrix. The predicted molecular mass is 34,699 Daltons.
Overexpression and purification  
of recombinant proteins under native 
conditions
Plasmid pHer-NLS was transformed into BL21(DE3)pLysS-
competent cells plated on Luria Bertani plates containing 
34 µg/mL of chloramphenicol and 100 µg/mL of ampicillin. 
Cultures were grown at 30°C until mid-log phase. Following 
induction with 1 mM IPTG, cells were grown at 20°C for 
eight hours. Briefly, bacterial cultures were harvested and the 
pellet was suspended in 25 mL lysis buffer (50 mM sodium 
phosphate buffer pH 7.0, 500 mM NaCl, 1 mM phenylmeth-
ylsulfonyl fluoride, and a cocktail protease inhibitor tablet) 
for 15 minutes and sonicated. The lysate was centrifuged at 
10,000 rpm for 30 minutes and filtered using 0.45 µm filters; 
1 mL of cobalt resin was added to the filtered supernatant, 
pre-equilibrated with lysis buffer, and incubated at 4°C for 
one hour. The resin containing the bound protein was washed 
with 10 mL wash buffer (50 mM sodium phosphate buffer 
pH 7.0, 500 mM NaCl, 10 mM imidazole, 1 mM phenylm-
ethylsulfonyl fluoride and eluted with 0.5 mL elution buffer 
(50 mM sodium phosphate buffer pH 7.0, 500 mM NaCl, 
250 mM imidazole, 1 mM phenylmethylsulfonyl fluoride, and 
a cocktail protease inhibitor tablet) in four fractions. The use 
of a cobalt affinity matrix (BD TALON; BD Biosciences, 
Palo Alto, CA) eliminated the binding of endogenous con-
taminating E. coli histidine-rich protein. The fractions were 
analyzed on 12% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), pooled, and passed through 
PD-10   desalting columns (BD Biosciences) with phosphate-
buffered saline at pH 7.4. The corresponding molecular 
mass of protein Her-NLS was analyzed by matrix-assisted 
laser desorption/  ionization time of flight mass spectrometry 
(MALDI-TOFMS). The final yield was typically 2 mg from 
a 1000 mL culture where the protein was greater than 95% 
homogeneous, as ascertained by SDS-PAGE.
Western blot analysis
Immunostaining of Her-NLS with anti-His antibody
Western blotting was done with purified proteins using 
monoclonal anti-His-antibodies against the 6 × His-tag fusion 
proteins, followed by binding to the secondary antibody 
coupled to alkaline phosphatase as described.5
HER2 receptor expression in breast cancer cells  
by immunostaining
Cell lysates for receptor quantitation prepared in 250 mM 
Tris-Cl pH 8.0, 0.5% NP-40 lysis buffer, and equal protein 
were loaded on a 6% sodium dodecyl sulfate gel after sonica-
tion. After electrophoresis, proteins were electroblotted onto a 
nitrocellulose membrane. Blots were probed with monoclonal 
antibody, anti-ErbB2 (intracellular domain) at 1:200 dilution 
and incubated overnight at 4°C, followed by incubation with 
a secondary antibody, antimouse-ALP (Bangalore Genei, 
Bangalore, India) 1:4000 for one hour at room temperature. 
Reactive bands were visualized with nitro blue tetrazolium 
chloride and 5-bromo-4-chloro-3- indoyl-1-phosphate.
DNA binding, electrophoretic mobility 
shift, and protection assays
Charge neutralization and DNA condensation of the fusion 
protein were observed by electrophoresis of the complexes 
on agarose gels as described previously.5 Briefly, plasmid 
DNA pEGFPN3 (0.2µg) was complexed with increasing 
amounts of protein Her-NLS to obtain the corresponding 
charge ratios, in Hepes-buffered saline (150 mM NaCl, 5 mM International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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KCl, 0.75 mM Na2HPO4, and 20 mM Hepes (pH 7.4) and 
incubated for 25 minutes at room temperature. The charge 
ratio of plasmid DNA to the fusion protein Her-NLS is 
indicated as D:P, and is calculated based on the   contribution 
by the negatively charged phosphates on DNA that was 
kept constant. The number of positive charges originating 
from Her-NLS is 51 and protamine sulfate is 20. In the 
case of DNA:Her-NLS:protamine sulfate, formulated at a 
1:8:2 charge ratio, protamine sulfate was added at 2 nmol 
of positive charge per nmol DNA and 8 nmol of Her-NLS. 
Complexes were then treated with DNase I at the indicated 
concentrations and processed by extraction with a mixture 
of phenol-chloroform. The complexes were subsequently 
analyzed on 1% agarose gel (Tris-acetate buffer system, pH 
8.2) and stained with ethidium bromide post electrophoresis. 
Binding is observed as retardation in the migration of the D:P 
complexes on an agarose gel.
Live uptake of plasmid pEGFPN3 
mediated by Her-NLS using confocal 
microscopy
MDA-MB-453 and MDA-MB- 231 cells were plated to 
about 70% confluence on chambered coverglass (Lab-
Tek, Nalge Nunc International Corp., Rochester, NY)   
and washed with serum-free DMEM (pH 7.4). Plasmid 
DNA pEGFPN3(0.45 µg) labeled with Oregon Green (Exλ 
493 nm, Emλ 520 nm) was mixed with an equal proportion 
of unlabeled plasmid and complexed with Her-NLS protein 
followed by further condensation with protamine sulfate. 
The cells were then incubated with the above complexes for 
three hours at 37°C and 5% CO2.   Subsequently, these were 
examined by confocal   microscopy to monitor the localization 
of the complexes within cells, along with a counter nuclear 
Hoechst 33258 stain. The image acquisition conditions for 
all the experiments were identical.
Preparation of transfection complexes
Plasmid DNA pCMVβ-gal or pEGFPN3 was purified using 
the Qiagen kit (endotoxin-free; Qiagen, GmbH, Hilden, 
Germany) according to the manufacturer’s protocol. Com-
plexes were prepared by taking 0.9 µg of plasmid DNA and 
varying amounts of the fusion protein to obtain the desired 
charge ratio and incubated for 25 minutes at room temperature 
in Hepes-buffered saline (pH 7.4). Transfection experiments 
were initially performed with Her-NLS and DNA complexes 
at varying charge ratios as described earlier. A charge ratio 
of 1:8 was found to be optimal for transfection. Protamine 
sulfate was added to these complexes to condense the DNA 
further at a charge ratio of DNA:protein:protamine sulfate 
1:8:2 and incubated for 25 minutes at room temperature. 
Complexes were then diluted with serum-free DMEM to a 
final volume of 300 µL. This was divided evenly into 100 µL 
volumes on a 96-well plate format containing 20,000 cells 
per well, to generate a triplicate set. The cells were incubated 
for at least three hours, following which complete medium 
with serum was added, and the reporter gene expression was 
assayed for β-galactosidase 24–48 hours post-transfection 
and the data analyzed as previously described.17
MTT assay
MDA-MB-231 and MDA-MB-453 were grown in a 96-well 
format to about 70% confluency. Complexes were prepared 
with DNA and Her-NLS and evaluated for their toxicity to 
cells by performing the MTT assay. Cells were incubated with 
transfection complexes for three hours at 37°C in serum-free 
DMEM. Soon after transfection, cells were rinsed with phos-
phate-buffered saline and replaced with 75 µL DMEM and 
25 µL MTT (2 mg/mL in phosphate-buffered saline) for three 
hours, after which the medium was aspirated and replaced with 
100 µL dimethyl sulfoxide:methanol 1:1 (v/v) and mixed to 
dissolve the formazan crystals. Absorbance was then measured 
at 540 nm, with untreated cells serving as controls.17
Results
Generation of plasmid pHer-NLS, 
overexpression, and purification  
of Her-NLS chimera
The motivation for this study originated from a need to add 
specificity to transfection peptides, such as the NLS, in order 
to target DNA eventually in a cell-specific manner into the 
nucleus. In this study, we have generated a recombinant fusion 
protein designated as Her-NLS, wherein the heregulin ligand 
was amplified and cloned in frame with three NLS peptides in 
tandem. Plasmid pHer-NLS, generated through this strategy, 
encodes an N-terminal His-tag protein which is driven by the 
T7 promoter. The reiteration of the NLS epitopes in a cationic 
fusion peptide, TAT-NLS-Mu, was reported to increase the 
efficiency of plasmid transfection significantly, as demon-
strated earlier4 in several mammalian cell lines.
Heregulin-α, a natural growth factor ligand, binds with 
high affinity to heterodimers of HER2/3 or HER2/4 tyrosine 
kinase receptor, p185erbB2, overexpressed in breast cancer cells, 
such as MDA-MB-453 and SK-OV-3. The cloned heregulin-α 
epitope in Her-NLS is the targeting ligand,   possessing the 
epidermal growth factor-like domain.   Figure 1A shows the 
schematic of the fusion construct generated wherein the NLS International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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epitopes have been cloned   in-frame with the heregulin-α 
moiety, primarily to facilitate DNA binding and cell-specific 
targeting. The cloned gene was verified for its authenticity 
by DNA sequencing prior to growth and overexpression in 
E. coli. Figure 1B depicts the translated single letter amino 
acid sequence of Her-NLS. The NLS epitopes and the target-
ing ligand are color-coded.
Production of Her-NLS by bacterial fermentation
Plasmid pHer-NLS was transformed and overexpressed 
in E. coli BL21 (DE3) pLysS as an N-terminal His-tag 
fusion protein. Her-NLS fusion protein was purified by 
native   conditions and   characterized for its biochemical 
and biological   properties in vitro. As seen in Figure 1A, 
the histidine tag at the N-  terminus of Her-NLS facilitated 
purification of the   recombinant proteins with a cobalt 
affinity matrix. Fractions were analyzed on 12% SDS gels, 
pooled, and desalted with PD-10 columns. Figure 1C shows 
an   SDS-PAGE analysis of the purified protein. This was 
confirmed by   immunoblotting using anti-His antibodies that 
confirmed the presence of a histidine tag in Her-NLS. The 
  corresponding molecular mass of the protein was further 
analyzed by MALDI-TOFMS which is 34,654 Daltons (not 
shown) and close to the expected value of 34,699 Daltons.
DNA binding activity of Her-NLS: protection  
by condenser protamine sulfate
Binding being the prerequisite for transfection, we next 
investigated the ability of purified recombinant Her-NLS to 
bind plasmid DNA. Complexes of DNA and protein were 
prepared at charge ratios of 1:8:2 and 1:8:3, incubated at 
room temperature for 25 minutes, and electrophoresed on 
an agarose gel. Complexes were viewed after staining with 
ethidium bromide postelectrophoresis, under ultraviolet light. 
The ability of Her-NLS protein to bind and protect DNA in 
the complex was investigated by incubating the complexes 
with DNase I (Figure 2). DNA binding is evident at charge 
ratios of 1:8. Further protection was observed in the presence 
of protamine sulfate, lanes 6 and 8. DNase I-treated samples 
were further extracted with phenol-chloroform and loaded, 
Figure 1 Construction and gel analysis of DNA-binding carrier protein Her-NLS. 
A) Schematic representation of chimeric fusion construct encoding the Her-NLS 
gene. The motifs harboring the NLS sequence (DPKKKRKV)3 were cloned in-frame 
with heregulin and expressed as N-terminal His-tag fusion protein in Escherichia coli. 
The plasmid is designated as pHer-NLS (not drawn to scale). B) Primary amino acid 
sequence (single amino acid code is color-coded) of the fusion protein Her-NLS based 
on DNA sequencing. NLS (blue), heregulin (red), and enterokinase cleavage site (green). 
The N-terminal His-tag is also depicted (cyan). The predicted molecular weight based 
on the sequence given is 34,699 Daltons. C) Sodium dodecyl sulfate-polyacrylamide gel 
electrophoretic analysis of the purified fusion proteins. Lanes correspond to Her-NLS 
after desalting from PD-10 columns. The molecular weight of the expressed proteins 
is 34,699 Daltons. Lane on the extreme right shows the immunoblot analysis of Her-
NLS after electrophoresis and transfer. The 6 × His tagged proteins were detected 
with monoclonal anti-His antibody followed by secondary antibody goat antimouse 
IgG alkaline phosphatase conjugate. Detection was by nitro blue tetrazolium chloride 
and 5-bromo-4-chloro-3-indoyl-1-phosphate treatment. 
Abbreviation: NLS, nuclear localization sequence.
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Figure 2 DNase I protection assay of the fusion protein Her-NLS. Plasmid pCMV- 
βgal (0.2µg) was incubated in 1 × Hepes buffer saline (pH 7.4) with increasing 
amounts of the purified protein corresponding to the charge ratio indicated above 
lanes 3, 5, and 7 (minus DNase I) and 4, 6, and 8 (plus DNase I). The samples were 
loaded along with control plasmid DNA (lane 1) and in the presence of DNase I 
(lane 2). Lanes 9 and 11 indicate untreated DNA:protamine sulfate complexes, while 
lanes 10 and 12 correspond to DNA:protamine sulfate complexes treated with 
DNase I. DNase I-treated samples were extracted with phenol-chloroform and 
loaded along with untreated samples and electrophoresed on 1% agarose gel in Tris-
acetate-ethylenediaminetetraacetate buffer. Gels were visualized by staining with 
ethidium bromide. 
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along with untreated samples, and electrophoresed on the 
same gel. Protected DNA, after phenol extraction, migrated 
normally as either relaxed or supercoiled DNA in lanes 6, 8, 
10, and 12, which indicates the extent of protection. Retarda-
tion of DNA in lanes 3, 5, and 7 arises from complexes of 
DNA and Her-NLS at charge ratios of 1:8, 1:8:2, and 1:8:3, 
respectively.
Our data suggest that Her-NLS binds DNA effi-
ciently, as seen from the retardation of complexes (lanes 
3, 5, and 7) on 1% agarose gel. Her-NLS also protects 
plasmid DNA pEGFPN3 from degradation by DNase I 
(lanes 4, 6, and 8) in the presence of protamine sulfate. 
The addition of protamine sulfate to DNA:Her-NLS com-
plexes (lanes 5 and 7) has further retarded the mobility 
of DNA, when compared with the migration of plasmid 
in lane 3, indicating enhanced protection in the presence 
of the condensing agent. As seen in lanes 6 and 8, the 
complexes are protected from digestion by DNase I, as 
seen from the intact supercoiled plasmid band. A positive 
control protamine sulfate complexed with DNA (lanes 
9–12), although less retarded on the agarose gel, resulted 
in the formation of a complex of lesser intensity, indicat-
ing the inaccessibility of DNA to ethidium bromide. In 
the absence of protein in lane 1, which is the control, both 
relaxed and supercoiled DNA migrated normally.
Her-NLS mediated uptake of DNA into MDA-
MB-453 cells in vitro
Live uptake of chimeric fusion complexes was examined by 
the addition of DNA:Her-NLS:protamine sulfate complexes 
at 1:8:2 charge ratio and visualized by confocal microscopy. 
It is evident that cell-associated particulate fluorescence was 
higher in MDA-MB-453 compared with MDA-MB-231 cells. 
Cells counterstained with Hoechst 33258 indicate sections 
in the nuclear region (Figure 3). Western blot analysis shows 
elevated levels of heregulin receptor expression when com-
pared with MDA-MB-231. As seen from Figure 4, MDA-
MB-453 cells overexpress the HER2 receptors (185 kDa) 
when compared with control MDA-MB-231 cells. Chinese 
hamster ovary cells served as a negative control.
Transfection mediated by Her-NLS in MDA-MB-453
Having characterized the potential for binding and selective 
uptake into MDA-MB-453, we performed transient transfec-
tion assays in vitro with the pCMVb-gal DNA:Her-NLS:PS 
complexes at a ratio of 1:8:2. This was to demonstrate 
primarily the targetability for HER2 receptors in MDA-
MB-453 (high HER2 expression) and MDA-MB-231 (low 
HER2 expression). MDA-MB-231 cells with low HER2 
levels was used as a control. This was on the premise that the 
targeting ligand would be   recognized by HER2/3 receptors 
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Figure 3 Confocal microscopy of uptake of transfection-competent complexes into MDA-MB-453 versus MDA-MB-231 cells. Confocal microscope analysis of uptake 
of Oregon green labeled-DNA:Her-NLS fusion protein complexes into cells. Peptide-mediated uptake of labeled DNA into MDA-MB-453 and MDA-MB-231 is seen as 
cell-associated fluorescence. DNA 0.9 µg was used to make the transfection complexes at a charge ratio of 1:8:2 (DNA:peptide:protamine sulfate) and applied to cells in 
the absence of serum. uptake of the complexes is for three hours’ duration, after which the cells were counterstained with Hoechst 33258, and visualized by confocal 
microscopy as described. 
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overexpressed in MDA-MB-453 cells. The addition of 
protamine sulfate to transfection   complexes, as seen from 
the DNA-binding assays, offered further   protection to DNA 
from degradation by   nucleases, as seen from the enhanced 
reporter gene expression, β-galactosidase,   mediated by 
D:Her-NLS:protamine sulfate, that is approximately 
  seven-fold higher than D:Her-NLS in MDA-MB-453 cells 
(see Figure 5). Cationic entities such as protamine,13,18 
polylysine, or NLS-containing peptides19,4 have been widely 
evaluated for their gene delivery potential and are frequently 
used to condense and protect plasmid DNA. As seen from 
the graph, under these conditions, a control cell line MDA-
MB-231, expressing basal levels of HER2/3, was not trans-
fected. Cationic peptide TNM or the Mu peptide that was used 
as a condenser, like protamine sulfate, conferred protection of 
DNA from degradation and brought about similar enhance-
ment in reporter gene expression (data not shown).
To examine if Her-NLS related toxicity had any effect 
on transfection efficiency, we also evaluated the effect of 
DNA:Her-NLS complexes on MDA-MB-231 and MDA-
MB-453 cells through an MTT assay (Figure 6) that indicated 
no apparent toxicity. This implies that these complexes are 
nontoxic to both MDA-MB-453 and MDA-MB-231 cells 
at the charge ratios tested. The fact that only MDA-
MB-453 cells were transfected indicates that the complexes 
were internalized by receptor-mediated endocytosis. It is 
purported that the cationic NLS epitopes may serve a dual 
role in terms of binding DNA and also nuclear localization, 
while the heregulin epitope recognizes the target receptor 
in MDA-MB-453 cells. NLS peptides alone do not have 
the specificity that is observed with Her-NLS (unpublished 
observations). Our data suggests that through modular design 
it is possible to achieve cell-specific targeting as a means of 
facilitating plasmid DNA delivery through receptor-ligand 
interactions. Such a strategy would enable the replacement of 
the heregulin ligand with other targeting moieties that would 
be suited to cell-specific delivery.
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37kDa
Figure 4 Expression of HER2/3 receptors in MDA-MB-231 and MDA-MB-453 cells 
by  Western  blotting.  MDA-MB-453  and  MDA-MB-231  cell  lysates,  normalized 
for  protein,  were  analyzed  on  6%  sodium  dodecyl  sulfate-polyacrylamide  gel 
electrophoretic  analysis  and  blotted  onto  a  nitrocellulose  membrane.  The  blot 
was probed using primary antibody ErbB2 (intracellular domain) against HER2/3 
receptors and treated with the secondary antibody antimouse IgG conjugated to 
alkaline phosphatase. Chinese hamster ovary cells were loaded as additional controls. 
Lysates for probing with antibodies to glyceraldehyde-3-phosphate dehydrogenase 
was also normalized and loaded separately on a 12% gel, and served as an internal 
loading control.
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Figure 5 Transient transfection of MDA-MB-453 cells versus MDA-MB-231 cells 
with Her-NLS fusion protein. Complexes were prepared with the fusion protein at a 
charge ratio of 1:8 and 1:8:2 of DNA+Her-NLS and DNA+Her-NLS+PS respectively. 
β-galactosidase activity was determined 48 hours post transfection. The plot depicts 
normalized mu β-galactosidase activity from plasmid pCMV β-gal.
Abbreviations: NLS, nuclear localization sequence; PS, protamine sulphate.
Figure  6  Toxicity  assay.  The  cytotoxicity  of  DNA-Her-NLS:protamine  sulfate 
complexes at varying concentrations of Her-NLS was evaluated in MDA-MB-231 
and MDA-MB-453 cells. The concentration of DNA:protamine sulfate was kept 
constant  at  1:2  charge  ratios.  Toxicity  was  measured  as  percent  viability  from 
absorption values obtained using reduced formazan, with cells in the absence of the 
complexes taken to be 100. 
Abbreviations: NLS, nuclear localization sequence; PS, protamine sulphate.
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Discussion
Peptides with targeting ligands are widely used in formula-
tions that facilitate specific DNA delivery into cells. Prior to 
the initiation of this work, it was hypothesized that fusion of 
the heregulin ligand with NLS would permit DNA binding, 
followed by uptake as a consequence of receptor-mediated 
endocytosis. In this study, we have successfully developed 
a novel, NLS-based peptide delivery system that can target 
ErbB2-overexpressing MDA-MB-453 breast cancer cells 
in vitro. We have demonstrated that Her-NLS indeed binds 
DNA and forms complexes, as seen from the particulate 
fluorescence in transfected MDA-MB-453 cells. Reporter 
gene expression was observed only in MDA-MB-453 cells, 
indicating that Her-NLS targets MDA-MB-453 breast cancer 
cells specifically at a ratio of 1:8:2 DNA:Her-NLS:protamine 
sulfate. It is evident that condensers, such as protamine sulfate 
used in the transfection assays, prevented the degradation 
of DNA by serum proteins because poor efficiencies were 
observed in its absence. We observed no increase in trans-
fection efficiency with Her-NLS/protamine sulfate alone 
on MDA-MB-453 cells. MDA-MB-231 with low levels of 
heregulin receptors is not transfected, indicating that receptor-
ligand interactions are crucial. As a consequence of these 
interactions, plasmid DNA gains entry specifically into MDA-
MB-453 that harbors an excess of HER2/3 receptors.
The approach of attaching protein-based targeting ligands 
for cell-specific targeting has been demonstrated earlier by 
Medina-Kauwe et al.20 In this study, the authors fused the 
penton base to polylysine and heregulin that enables targeting 
breast cancer cells specifically, while retaining the property 
of DNA binding through a polylysine stretch of 10 residues 
and also facilitating endosomal escape. A linear sequence 
of   positive charges, as in poly-L-lysine, has earlier been 
shown to be insufficient for transfection,21 indicating the 
role of   peptide sequences for efficient   binding and DNA 
  condensation. Although polylysine has been used   extensively 
in gene delivery,22,23 it is accompanied with   considerable tox-
icity,24,25 and is now used only when   chemically modified.
A major limitation to gene transfer is the entry of plasmid 
DNA from the cytoplasm to the nucleus. Strategies for the use 
of NLS bioconjugates that utilize the cytoplasmic machinery 
to shuttle bound nucleic acids efficiently into the nucleus have 
been discussed.26 Xavier et al have demonstrated that a recom-
binant peptide with three NLS epitopes in tandem, facilitates 
DNA delivery.4 The Her-NLS generated in this study appar-
ently increases nuclear entry soon after receptor-mediated 
internalization of the complexes in MDA-MB-453 cells. It 
is possible that the binding efficiency of Her-NLS to DNA 
is facilitated by the presence of arginine and lysine residues 
present in multiple copies or overall basicity of the protein. 
The NLS epitopes may enable rapid transit of endocytosed 
complexes which are then rapidly delivered into the nucleus, 
possibly by interaction with importins in the cellular milieu, 
resulting in enhancement of β-galactosidase reporter gene 
expression in MDA-MB-453 cells. Puri et al have observed 
that HER2 specific affibody-conjugated liposomes improve 
the delivery of anticancer agents in a cell-specific manner.8 
These efforts require the use of formulations that would be 
suitable for combination therapies. Our strategy employs two 
epitopes, engineered to bind DNA and target cancer cells 
overexpressing the heregulin receptor in vitro. At the optimal 
ratios, complexes are internalized in MDA-MB-453 human 
breast cancer cells, possibly via receptor-specific binding and 
internalization into the cytoplasm followed by rapid entry into 
the nucleus. Her-NLS renders efficient targeting in vitro via 
the cloned heregulin. Furthermore, the NLS peptides fused 
to the Her moiety, through its NLS (PKKKRK)3-enhanced 
nuclear entry, resulting in high gene expression in vitro. This 
delivery system lays the foundation for further development 
of effective therapeutic molecules for delivery of plasmid 
DNA and other siRNA. The study also demonstrates the scope 
for further development of nonviral carriers by generating 
minimal sequences for cell-specific nucleic acid delivery. 
This is possibly the first demonstration with NLS-containing 
epitopes fused to heregulin ligand for efficient targeting into 
cells expressing the HER2 receptor. Apart from TAT, other 
cationic-nucleic acid-binding modules, such as the NLS or 
multiple copies of Mu, could be cloned along with double-
stranded RNA-binding domain and targeting ligands in one 
frame to introduce multifunctionality. This would permit 
specific interaction with the siRNA that can target cells 
specifically via epitopes engineered into one recombinant 
protein molecule. This also translates to a multidomain fusion 
peptide that would be a single entity having modules that 
could be replaced depending on the recipient cell. It is also 
possible to replace heregulin, the targeting ligand, with other 
peptide ligands that recognize its corresponding receptors 
on other cell types in the context of siRNA or plasmid DNA 
delivery. This work is currently in progress.
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